Acute Lymphocytic Leukemia Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings

Data from the following clinical trials are discussed:

• ASCO 7009: A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
• ASCO e19003: A phase 1b study of blinatumomab with the anti-programmed cell death (PD)-1 antibody AMG 404 in adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL)
• ASCO 7034: A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL)
• ASCO 7011: Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL)
• EHA P353: Forty Months of the Gimema LAL2116 (D-ALBA) Protocol and Ancillary LAL2217 Study for Newly Diagnosed Adult PH+ ALL
• EHA P366: Blinatumomab Added to Prephase and Consolidation Therapy in Newly Diagnosed Precursor B-ALL in Adults. A Phase II Hovon Trial
• EHA PB1762: Ponatinib Versus Imatinib with Reduced – Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosone-Positive (PH+) Acute Lymphoblastic Leukemia (ALL): PHALLCON Study
• EHA PB1749: Apoptotic Effect of Flumatinib Combined with BCL2 Inhibitor on PH+ B-Cell Acute Lymphoblastic Leukemia